Maia Biotechnology, INC. 8-K Filing
Ticker: MAIA · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1878313
Sentiment: neutral
Filing Stats: 769 words · 3 min read · ~3 pages · Grade level 14.7 · Accepted 2025-12-10 16:15:42
Key Financial Figures
- $50B — s release entitled "MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough
Filing Documents
- form8-k.htm (8-K) — 39KB
- ex99-1.htm (EX-99.1) — 23KB
- ex99-1_001.jpg (GRAPHIC) — 14KB
- 0001493152-25-027072.txt ( ) — 253KB
- maia-20251210.xsd (EX-101.SCH) — 3KB
- maia-20251210_lab.xml (EX-101.LAB) — 33KB
- maia-20251210_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 10, 2025 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3